Senicapoc
 | |
| Names | |
|---|---|
| IUPAC name
2,2-bis(4-fluorophenyl)-2-phenylacetamide | |
| Identifiers | |
289656-45-7  | |
| ChemSpider | 187516  |
| |
| Jmol-3D images | Image |
| KEGG | D06640 |
| PubChem | 216327 |
| |
| Properties | |
| C20H15F2NO | |
| Molar mass | 323.34 g/mol |
| Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
| verify (what is: /?) | |
| Infobox references | |
Senicapoc (ICA-17043) is a Gardos channel blocker.[1][2]
It has been proposed for use in sickle cell anemia.[3]
The Gardos channel has been identified as KCNN4.[4]
The "ICA" is for Icagen, which is developing the drug.[5]
References
- ↑ Ataga KI, Smith WR, De Castro LM et al. (April 2008). "Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia". Blood 111 (8): 3991–7. doi:10.1182/blood-2007-08-110098. PMID 18192510.
- ↑ McNaughton-Smith GA, Burns JF, Stocker JW et al. (February 2008). "Novel inhibitors of the Gardos channel for the treatment of sickle cell disease". J. Med. Chem. 51 (4): 976–82. doi:10.1021/jm070663s. PMID 18232633.
- ↑ Ataga KI, Stocker J (February 2009). "Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia". Expert Opin Investig Drugs 18 (2): 231–9. doi:10.1517/13543780802708011. PMID 19236269.
- ↑ Hoffman JF, Joiner W, Nehrke K, Potapova O, Foye K, Wickrema A (June 2003). "The hSK4 (KCNN4) isoform is the Ca2+-activated K+ channel (Gardos channel) in human red blood cells". Proc. Natl. Acad. Sci. U.S.A. 100 (12): 7366–71. doi:10.1073/pnas.1232342100. PMC 165881. PMID 12773623.
- ↑ "Icagen - Press Release". Retrieved 2008-12-22.